What are the recommended doses of adenosine for treating supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Adenosine Dosing for Supraventricular Tachycardia (SVT)

For adult patients with SVT, adenosine should be administered as an initial 6 mg rapid IV bolus, followed by 12 mg if no response within 1-2 minutes, with the option to repeat the 12 mg dose once more if necessary. 1

Standard Adult Dosing Protocol

  • Initial dose: 6 mg rapid IV bolus
  • If no response in 1-2 minutes: 12 mg rapid IV bolus
  • If still no response: May repeat 12 mg dose once more
  • Maximum total dose: 30 mg (6 mg + 12 mg + 12 mg)

Administration Technique

  • Administer as rapid IV bolus (over 1-2 seconds)
  • Inject as proximal or as close to the heart as possible
  • Follow immediately with rapid saline flush
  • Continuous ECG monitoring during administration is essential

Dose Adjustments for Special Populations

Reduced Initial Dose (3 mg) for:

  • Patients taking dipyridamole or carbamazepine
  • Heart transplant recipients
  • When administered via central venous access 2

Increased Initial Dose for:

  • Patients with significant blood levels of theophylline, caffeine, or theobromine 2

Pediatric Dosing:

  • Initial dose: 0.05 mg/kg
  • Can increase in increments of 0.05 mg/kg every 1-2 minutes
  • Maximum dose: 0.25 mg/kg 3

Efficacy and Safety Considerations

Adenosine is highly effective for SVT involving the AV node, with effectiveness rates of 90-95% for atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) 2. Recent evidence suggests that an initial dose of 12 mg may be associated with:

  • Less need for re-dosing
  • Greater rates of patient improvement
  • Lower rates of hospital admission 4

However, the current guidelines still recommend the 6 mg initial dose for standard practice.

Precautions and Contraindications

Use with Caution or Avoid in:

  • Patients with asthma or bronchospastic lung disease (contraindicated)
  • Patients with pre-excitation syndromes (risk of accelerated conduction through accessory pathway)
  • Severe heart block 2

Common Side Effects (Usually Transient):

  • Flushing
  • Chest pain
  • Dyspnea
  • Transient AV block
  • Potential for bronchospasm (rare)
  • Potential to initiate atrial fibrillation 1

Special Considerations

  • Adenosine is safe in pregnancy due to its extremely short half-life 2
  • In patients with impaired venous return (e.g., right heart failure), higher-than-recommended doses may occasionally be necessary for effective termination of SVT 5
  • The safe use of 18-mg bolus doses has been reported in the literature 1

For refractory cases not responding to maximum adenosine doses, alternative treatments such as calcium channel blockers, beta-blockers, or electrical cardioversion should be considered based on the patient's clinical status.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Adenosine Therapy for Supraventricular Tachycardia (SVT)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Adenosine administration for neonatal SVT.

Neonatal network : NN, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.